Xcellerant Ventures Invests in CRISPR QC’s $10 Million Series A Round

Xcellerant Ventures is excited to invest in CRISPR QC, a San Diego biotech company. They’ve created a groundbreaking platform that assesses the quality of the CRISPR/CAS9 gene editing system. This tool helps pharmaceutical and agriculture companies choose the most effective and accurate therapies for personalized medicines quickly.

CRISPR QC is a top player in genetic medicine. Their CRISPR Analytics Platform gives researchers and biotech firms worldwide new data on editing activity. They focus on improving CRISPR-Cas function, offering key insights that speed up the development of groundbreaking therapies and agricultural progress.

Ross Bundy, CEO of CRISPR QC said in a statement:

“We have spoken with several venture funds who have strong interest in our technology, but we were looking for the ideal partner who could help us the most with our commercialization plans. It was instantly clear to us that Xcellerant Ventures was the investor and partner we have been searching for, and we are excited and honored to have Xcellerant lead our Series A.”

Xcellerant Ventures, based in Phoenix, is a forward-thinking venture capital firm. They invest in early-stage startups in HealthTech, MedTech, and BioTech, aiming to spot and support the newest trends revolutionizing healthcare. Xcellerant Ventures will be taking the lead in investing in CRISPR QC’s $10 Million Series A round. They’ll also provide guidance as a board member. This investment led to CRISPR QC setting up an office in Scottsdale to tap into Arizona’s expertise in semiconductors and medical devices.

Chris Yoo, Ph.D., GP of Xcellerant Ventures, added:

“With CRISPR-based gene editing, we are at the beginning of a truly precise way to treat and cure thousands of genetically-driven diseases. We strongly believe CRISPR QC will be one of the required technologies for any company that wants to be in the business of developing personalized medicines.”